NCT03856112 2019-03-26
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Mirna Therapeutics, Inc.
La Jolla Pharmaceutical Company